Gossamer Bio Converts $181M of 2027 Notes Into New Secured Debt and Equity (NASDAQ: GOSS)

Gossamer Bio, Inc. (NASDAQ: GOSS) completed a debt exchange offer that converted $181 million of its 2027 convertible senior notes into a combination of new secured notes due 2030 and equity. The transaction restructures the company's balance sheet as it advances seralutinib, its lead candidate for the treatment of pulmonary arterial hypertension (PAH). Shares gained 6.74% on Wednesday, June 17, 2026, closing at $0.18.

Deal Terms

• $181M of 2027 convertible senior notes were tendered and exchanged in the offer, per the company's announcement.
• $72M in new secured notes due 2030 were issued as part of the exchange consideration.
• 317.6 million shares were made available to participating noteholders as equity consideration.
• $18.95M of the original 2027 notes remain outstanding following the close of the exchange.
• The new notes carry a secured structure, elevating their priority in the capital stack relative to the prior unsecured convertible instruments.

Why It Matters

The exchange offer substantially reduces the near-term maturity risk that the 2027 notes represented, replacing the bulk of that obligation with secured paper maturing in 2030 and a meaningful equity component. By pushing the debt maturity out by approximately three years, Gossamer extends the runway available to advance seralutinib through its clinical and regulatory timeline without the pressure of a 2027 repayment event looming over the balance sheet.

The issuance of 317.6 million shares as exchange consideration does introduce dilution for existing equity holders, a direct cost of the recapitalization. The $18.95 million in old 2027 notes that were not tendered remain a residual liability, though that figure is materially smaller than the original $181 million face value that entered the exchange. The secured nature of the new 2030 notes means those instruments now rank ahead of any remaining unsecured claims, concentrating recovery priority among participating creditors.

Wall Street View

Analyst sentiment on GOSS as of June 1, 2026, skewed constructive, with 2 Strong Buy, 6 Buy, 5 Hold, and 1 Sell recommendation in the current consensus. That compares to a prior-period breakdown of 3 Strong Buy, 6 Buy, and 6 Hold, reflecting a modest shift in the distribution. No specific price targets were disclosed in connection with the exchange announcement.

Investor Takeaway

The completed exchange removes $181 million of 2027 maturity risk from Gossamer's balance sheet and replaces it with $72 million in new secured 2030 notes plus equity, buying the company additional time to generate clinical data on seralutinib in PAH. The 317.6 million shares issued as consideration represent meaningful dilution, and the $18.95 million in unretendered 2027 notes remain on the books. For investors, the key question is whether the extended debt runway is sufficient to reach a value-creating clinical or regulatory milestone before the new 2030 maturity arrives.